Magara Anouk, Bühler Robert, Moser David, Kowalski Milek, Pourtehrani Payam, Jeanmonod Daniel
Praxis für Neurologie, Monbijoustrasse 73, 3007 Bern, Switzerland.
Neurological Division, Bürgerspital Solothurn, Schöngrünstrasse 38, 4500 Solothurn, Switzerland.
J Ther Ultrasound. 2014 May 31;2:11. doi: 10.1186/2050-5736-2-11. eCollection 2014.
Radiofrequency (RF) subthalamotomies have been proposed since the 1960s to treat patients suffering from Parkinson's disease (PD). Recently, the magnetic resonance (MR)-guided focused ultrasound technology (MRgFUS) offers the possibility to perform subthalamic thermocoagulations with reduced risks and optimized accuracy. We describe here the initial results of the MRgFUS pallidothalamic tractotomy (PTT), an anatomical and physiological update of the earlier subthalamotomies.
Thirteen consecutive patients suffering from chronic (mean disease duration 9.7 years) and therapy-resistant PD were treated unilaterally with an MRgFUS PTT. Primary relief assessment indicators were the score reduction of the Unified Parkinson Disease Rating Scale (UPDRS) and the patient estimation of global symptom relief (GSR) taken at 3 months follow-up. Final temperatures at target were between 52°C and 59°C. The MR examinations were performed before the treatment, 2 days and 3 months after it. The accuracy of the targeting was calculated on 2 days post-treatment MR pictures for each PTT lesion.
The first four patients received a PTT using the lesional parameters applied for thalamotomies. They experienced clear-cut recurrences at 3 months (mean UPDRS relief 7.6%, mean GSR 22.5%), and their MR showed no sign of thermal lesion in T2-weighted (T2w) images. As a consequence, the treatment protocol was adapted for the following nine patients by applying repetition of the final temperatures 4 to 5 times. That produced thermocoagulations of larger volumes (172 mm(3) against 83 mm(3) for the first four patients), which remained visible at 3 months on T2w images. These nine patients enjoyed a mean UPDRS reduction of 60.9% and a GSR of 56.7%, very close to the results obtained with radiofrequency lesioning. The targeting accuracy for the whole patient group was 0.5, 0.5, and 0.6 mm for the anteroposterior (AP), mediolateral (ML), and dorsoventral (DV) dimensions, respectively.
This study demonstrated the feasibility, safety, and accuracy of the MRgFUS PTT. To obtain similar results as the ones of RF PTT, it was necessary to integrate the fact that white matter, in this case, the pallidothalamic tract, requires repeated thermal exposition to achieve full lesioning and thus full therapeutic effect.
自20世纪60年代以来,射频(RF)丘脑底核切开术就被用于治疗帕金森病(PD)患者。近年来,磁共振(MR)引导聚焦超声技术(MRgFUS)为实施丘脑底核热凝术提供了可能,且风险更低、准确性更高。在此,我们描述MRgFUS苍白球丘脑束切断术(PTT)的初步结果,这是对早期丘脑底核切开术在解剖学和生理学方面的更新。
连续13例患有慢性(平均病程9.7年)且对治疗耐药的PD患者接受了单侧MRgFUS PTT治疗。主要缓解评估指标为随访3个月时统一帕金森病评定量表(UPDRS)评分降低情况以及患者对整体症状缓解(GSR)的评估。靶点处最终温度在52°C至59°C之间。在治疗前、治疗后2天和3个月进行MR检查。根据治疗后2天的MR图像计算每个PTT病变的靶点定位准确性。
前4例患者接受的PTT采用了用于丘脑切开术的毁损参数。他们在3个月时出现明显复发(平均UPDRS缓解率7.6%,平均GSR 22.5%),其MR的T2加权(T2w)图像上未显示热损伤迹象。因此,对后续9例患者调整了治疗方案,将最终温度重复施加4至5次。这产生了更大体积的热凝(前4例患者为83立方毫米,后9例患者为172立方毫米),在3个月时T2w图像上仍可见。这9例患者的UPDRS平均降低60.9%,GSR为56.7%,非常接近射频毁损术的结果。整个患者组在前后(AP)、内外侧(ML)和上下(DV)维度的靶点定位准确性分别为0.5毫米、0.5毫米和0.6毫米。
本研究证明了MRgFUS PTT的可行性、安全性和准确性。为获得与RF PTT相似的结果,有必要考虑到在这种情况下白质,即苍白球丘脑束,需要反复热暴露以实现完全毁损,从而达到完全治疗效果。